Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRONDOSE: High vs Low Dose IV Iron in HF
NCT06427343Phase 4Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Oct 2023
- Primary completion
- Sep 2026
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferric derisomaltose in iron deficiency anemia (IDA) (2 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: Change in peak oxygen uptake at 52 weeks. Started Oct 2023; status: recruiting.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT06427343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427343.